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omplex Trait Genetics
he Role of Mechanistic
Intermediate Phenotypes”
nd Candidate Genetic Loci*
angwen Rao, MD, Lian Zhang, MD,
aniel T. O’Connor, MD
an Diego, California
oronary Artery Disease Risk
lthough coronary artery disease (CAD) is the most com-
on type of heart disease, its etiology and pathogenesis are
ot well understood. Hereditary determination of CAD is
uggested by epidemiologic studies in which first-degree
elatives of coronary patients have a 2.5- to 7-fold increase
n risk of death from coronary disease compared with those
ithout a family history of CAD (1). Young adults with a
amily history of premature CAD are likely to have the
trongest genetically determined influence on their risk of
ubsequent arterial disease (2). Despite increased under-
tanding of rare mendelian contributors to CAD (e.g.,
amilial dyslipidemias [3,4]), the common presentation of
AD is likely to be a complex trait, with both hereditary
nd environmental determination (2,5).
See page 158
Experimental and clinical studies suggest that endo-
helial dysfunction may be a precursor to CAD (2,6).
aintenance of endothelial function is a critical aspect of
ascular homeostasis. The gaseous transmitter nitric oxide
NO), derived from 3 nitric oxide synthase (NOS) isoforms,
lays a key role in vascular tone, and alterations in NO
roduction influence endothelium-dependent vasodilation
nd blood pressure. Loss of normal endothelial production
f NO is an early and characteristic feature of many vascular
isease states and plays a role in disease pathogenesis (7).
lterations of NO availability may be involved in the
enesis of atherosclerosis, and thus may contribute to
rogression of CAD (7).
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Departments of Medicine and Pharmacology, Center for Human
enetics and Genomics, University of California at San Diego, and Veteransi
dministration San Diego Healthcare System, San Diego, California. Supported by
he Department of Veterans Affairs, National Institutes of Health.ascular Risk Mechanisms and Heredity
everal major cardiovascular risk factors, such as hyperten-
ion (8,9) and dyslipidemia (3,8), are known to be geneti-
ally influenced. In twin studies, human NO production
isplays substantial heritability and joint genetic determina-
ion with autonomic activity (5). In humans, a variant of the
ndothelial NO synthase gene (eNOS, NOS3) within exon 7
GT transversion at nucleotide position 894 [G894T],
esulting in a change of Glu298Asp) predicts enhanced
esponsiveness to alpha-adrenergic stimulation (10). In an
xamination of the effect of G894T polymorphism on the
ndothelium in subjects with premature myocardial infarc-
ion (11), the 894T (298Asp) allele was associated with
mpaired vasodilation and higher levels of von Willebrand
actor.
In the face of significant heritability yet uncertain mode
f inheritance for complex traits such as CAD, a useful
trategy may be to establish so-called “intermediate pheno-
ypes” (12): ideally, pathogenic traits with early expression
ven before disease onset.
ole of GTP Cyclohydrolase (GCH1)
olymorphism on Endothelial Function
uanosine triphosphate (GTP) cyclohydrolase I (GCH1)
atalyzes the first and rate-limiting step in tetrahydrobiop-
erin (BH4) biosynthesis. Tetrahydrobiopterin is an essen-
ial cofactor for several transmitter biosynthetic pathway
nzymes, including not only the 3 NOS but also tyrosine
ydroxylase (TH), phenylalanine hydroxylase, and trypto-
han hydroxylase. The human GCH1 locus experiences rare
atural inactivating mutations with profound consequences;
uch mutations cause 2 disorders: autosomal dominant
ereditary progressive dystonia/DOPA-responsive dystonia
HPD/DRD) and autosomal recessive GCH1-deficient
yperphenylalaninemia (HPA). Biochemical characteriza-
ions of these diseases demonstrate lower cerebrospinal fluid
evels of BH4 and the BH4 pathway metabolite neopterin
13). A mouse model for dominantly inherited GCH1
eficiency also showed low brain levels of BH4 (13). Earlier
tudies in cultured cells showed that GCH1 inhibition
owers BH4 levels, leading to decreased NO production
14). Exogenous BH4 in the spontaneously (genetic) hyper-
ensive rat can prevent development of elevated BP (15).
In states such as atherosclerosis (16), diabetes mellitus,
ypertension (17), or insulin resistance, vascular BH4 defi-
iency may be mediated, at least in part, by increased
ntracellular oxidation of BH4 to BH2 by reactive oxygen
pecies (such as peroxynitrite) (16).
Other studies suggest that changes in BH4 biosynthesis,
erhaps through regulation of the rate-limiting enzyme
CH1 (18) or dihydropteridine reductase (19), may also be
mportant for vascular BH4 bioavailability.
The gaseous transmitter NO plays a critical role in
ndothelium-dependent vasodilation and BP. Understand-
ng the full spectrum of genes that influence NO production
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July 8, 2008:166–8 Editorial Commentight thus contribute to an improved understanding of
AD. As reported in this issue of the Journal, Antoniades et
l. (20) studied endothelium-dependent dilation (to acetyl-
holine), as well as GCH1 expression, BH4 bioavailability,
O bioavailability, and vascular superoxide production in
aphenous vein (SV) and internal mammary artery (IMA)
egments from 347 patients with CAD undergoing coro-
ary artery bypass grafting (CABG) surgery in the United
ingdom.
The researchers (20) defined GCH1 haplotypes first by
enotyping 347 patients with coronary artery disease and
41 control subjects. Three SNPs spanning the locus
promoter GA, rs8007267; intron-1 AT, rs3783641;
=-UTR CG, rs10483639) were sufficient to define hap-
otypes. Common haplotype ATG (the third most common
aplotype in the population [21], designated “X” by the
uthors) accounted for 15% of chromosomes, and did not
iffer significantly in frequency between CAD and control
ubjects. However, haplotype X had pronounced effects on
everal “intermediate phenotypes” for vascular risk, includ-
ng reduction in GCH1 vascular gene (messenger ribonu-
leic acid) expression, reduction in plasma and vascular BH4
oncentrations, increased vascular superoxide production,
nd decreased vascular dilation to an endothelium-
ependent stimulus (acetylcholine in this case). In multi-
ariate analyses of several risk predictors, GCH1 haplotype
as an independent predictor of reduced BH4 levels in both
lasma and vascular tissue.
he Current Results in Context With the Literature
he impact of common genetic variation in GCH1 for BH4
and therefore NO) production has only recently been
ubjected to another study in humans (19), whose results
ay be complementary to the current report: systematic
olymorphism discovery across the GCH1 locus (exons and
romoter) revealed 13 common single nucleotide variants.
n a series of twin pairs phenotyped for autonomic and renal
raits, urinary NO (estimated by nitrate/nitrite) excretion
as influenced by GCH1 polymorphism, and the effect was
apped onto a common variant in the 3=-UTR: C243T
rs841). This same 3=-UTR polymorphism coordinately
redicted not only NO production but also baroreflex
oupling, heart rate variability, and minimum heart rate. In
primary care population, 3=-UTR variant C243T influ-
nced both SBP and DBP. One is tempted to speculate that
rait-associated allele in the GCH1 3=-UTR (C243T)
ight be responsible for the vascular findings from Anto-
iades et al. (20). However, an additional 13 common SNPs
ere discovered in this gene, with 3 located in the promoter
egion (5); therefore, different polymorphic sites might alter
unction in alternative tissues (coronary artery versus kid-
ey). The precise nature and roles of causative variants in
ascular tissues remain to be established.mplications of This Research
he current study (20) represents the first attempt to
haracterize GCH1 gene variability to detect functionally
mportant changes in patients with CAD. Careful pheno-
yping allowed the authors to detect the effects of GCH1
ommon variation on important risk traits, both biochem-
cal and pharmacologic, even though the active haplotype
id not associate with the ultimate disease trait in the CAD
ase/control study. Thus, the importance of mechanistic
henotyping is highlighted by this report.
The results in the GCH1/NO pathway also emphasize
he likely utility of this pathway in design of future thera-
eutics targeting endothelial function (22) and ultimately
AD risk. The GCH1 genotypes might be useful in
efining the pathogenesis of risk, as well as quantitatively
rofiling such risk or the likelihood that pathway-directed
herapeutics (e.g., BH4) would be effective in a given
ndividual (i.e., GCH1 pharmacogenetics). Indeed, stable
ral BH4 supplementation is now effective in a subset of
ubjects with autosomal recessive phenylalanine hydoxylase
eficiency (23), although the successful use of BH4 supple-
entation in cardiovascular disease has not yet advanced
eyond the experimental animal stage (24).
eprint requests and correspondence: Dr. Daniel T. O’Connor,
epartment of Medicine (0838), UCSD School of Medicine and
ASDHS, 9500 Gilman Drive, La Jolla, California 92093-0838.
-mail: doconnor@ucsd.edu.
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